丹参酮IIA通过WTAP介导的m⁶A甲基化抑制糖尿病肾病中系膜细胞的增殖和纤维化。
Tanshinone IIA suppresses the proliferation and fibrosis of mesangial cell in diabetic nephropathy though WTAP-mediated mA methylation.
作者信息
Peng Hao, Zhang Xiaoyan
机构信息
Department of Endocrine, Xiangyang Hospital of Traditional Chinese Medicine (Xiangyang Institute of Traditional Chinese Medicine), Xiangyang City, Hubei Province, China.
Department of Oncology, Xiangyang Hospital of Traditional Chinese Medicine (Xiangyang Institute of Traditional Chinese Medicine), No. 112, Changzheng Road, Fancheng District, Xiangyang City, 441000, Hubei Province, China.
出版信息
Sci Rep. 2025 Jul 1;15(1):21261. doi: 10.1038/s41598-025-03738-6.
Diabetic nephropathy (DN) is often accompanied by mesangial cell proliferation and fibrosis. Tanshinone IIA (Tan-IIA) is the main fat-soluble component of Salvia miltiorrhiza. N6-Methyladenosine (mA) modification is a widely studied epigenetic mechanism. This study aimed to investigate the role of Tan-IIA in DN and the underlying mechanism. Cell viability and proliferation were assessed via cell counting kit-8 and ethynyldeoxyuridine assays. Protein levels of fibrosis-related indicators were detected by Western blot. Reverse transcription-quantitative polymerase chain reaction was used to detect the levels of mA-related enzymes. The interaction betweenWT1 associated protein (WTAP) and prolactin receptor (PRLR) was examined through RNA immunoprecipitation and dual-luciferase reporter assays. The animal DN models was established. Biochemical measurements of rat serum were performed using commercial kits. Hematoxylin&eosin and Masson trichrome staining were used for histopathological analysis. Results showed that Tan IIA treatment inhibited the cell proliferation and fibrosis of human renal mesangial cells (HRMCs). Besides, Tan IIA treatment regulated WTAP-mediated mA modification. Overexpression of WTAP upregulated the cell proliferation and fibrosis of HRMCs. Mechanically, WTAP enhanced the stability of PRLR mRNA via mA methylation. Subsequent rescue investigations revealed that overexpression of PRLR increased the cell proliferation and fibrosis of HRMCs. In the in vivo study, Tan IIA treatment reversed the renal injury in rats and decreased the protein levels of WTAP, PLRP, and fibrosis-related indicators in kidney tissues. Tan IIA suppressed the proliferation and fibrosis of HRMCs in DN though WTAP-mediated mA methylation of PRLR.
糖尿病肾病(DN)常伴有系膜细胞增殖和纤维化。丹参酮IIA(Tan-IIA)是丹参的主要脂溶性成分。N6-甲基腺苷(mA)修饰是一种广泛研究的表观遗传机制。本研究旨在探讨Tan-IIA在DN中的作用及潜在机制。通过细胞计数试剂盒-8和乙炔基脱氧尿苷试验评估细胞活力和增殖。采用蛋白质印迹法检测纤维化相关指标的蛋白水平。逆转录定量聚合酶链反应用于检测mA相关酶的水平。通过RNA免疫沉淀和双荧光素酶报告基因试验检测WT1相关蛋白(WTAP)与催乳素受体(PRLR)之间的相互作用。建立动物DN模型。使用商业试剂盒对大鼠血清进行生化检测。苏木精-伊红染色和Masson三色染色用于组织病理学分析。结果表明,Tan IIA处理抑制了人肾系膜细胞(HRMCs)的细胞增殖和纤维化。此外,Tan IIA处理调节了WTAP介导的mA修饰。WTAP的过表达上调了HRMCs的细胞增殖和纤维化。机制上,WTAP通过mA甲基化增强了PRLR mRNA的稳定性。随后的挽救研究表明,PRLR的过表达增加了HRMCs的细胞增殖和纤维化。在体内研究中,Tan IIA处理逆转了大鼠的肾损伤,并降低了肾组织中WTAP、PLRP和纤维化相关指标的蛋白水平。Tan IIA通过WTAP介导的PRLR的mA甲基化抑制了DN中HRMCs的增殖和纤维化。